Goresp Digihaler (Budesonide, Formoterol Fumarate Dihydrate)

Goresp Digihaler is indicated for the long‑term, regular treatment of two chronic respiratory conditions.

• Maintenance therapy for asthma in adults and adolescents who require both anti‑inflammatory and bronchodilator effects.
• Maintenance therapy for chronic obstructive pulmonary disease (COPD) to reduce exacerbations and improve lung function.
• Use as a step‑up therapy when asthma is not adequately controlled by inhaled corticosteroid alone.
• Suitable for patients who prefer a digital inhaler with dose‑counting and adherence monitoring.
• Can be part of a comprehensive asthma or COPD management plan that includes trigger avoidance and regular follow‑up.

Side effects of Goresp Digihaler reflect the combined actions of an inhaled corticosteroid and a long‑acting β2‑agonist.

Common

• Hoarseness or throat irritation after inhalation.
• Oral candidiasis (thrush) due to local corticosteroid effect.
• Cough or mild bronchospasm immediately after use.
• Headache or mild dizziness.
• Nasal congestion or sinus discomfort.
• Transient increase in heart rate.

Serious

• Severe allergic reaction such as angioedema or anaphylaxis.
• Paradoxical bronchospasm that worsens breathing.
• Persistent high blood pressure or cardiac arrhythmia.
• Signs of adrenal suppression with long‑term high‑dose corticosteroid use.

Before prescribing Goresp Digihaler, clinicians should consider several safety aspects.

• Assess for a history of hypersensitivity to budesonide, formoterol, or any excipients.
• Use the lowest effective dose to minimize systemic corticosteroid exposure.
• Monitor patients for oral thrush and advise rinsing the mouth after inhalation.
• Caution in patients with cardiovascular disease, uncontrolled hypertension, or arrhythmias.
• Evaluate bone health in long‑term users, especially those at risk for osteoporosis.
• Advise pregnant or breastfeeding women to discuss potential risks with their healthcare provider.

Goresp Digihaler may interact with other medications that affect the cardiovascular or metabolic systems.

Avoid

• Concomitant use of non‑selective β‑blockers, which can diminish bronchodilator response.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) that may increase systemic exposure to formoterol.
• Systemic corticosteroids at high doses, which can increase risk of adrenal suppression.

Use with caution

• Diuretics or antihypertensive agents, as β2‑agonists may cause mild increases in blood pressure.
• Monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants, due to potential additive cardiovascular effects.
• Other inhaled or oral corticosteroids, requiring careful monitoring of total steroid load.